Search results for " Antibodies"

showing 10 items of 383 documents

Migraine and cluster headache – the common link

2018

Abstract Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability…

medicine.medical_specialtyNeurologyCluster headacheImplantable Neurostimulators/statistics & numerical dataPain medicineCalcitonin Gene-Related PeptideDeep Brain StimulationMigraine DisordersNitroglycerin/adverse effectsHypothalamuslcsh:MedicineTriptansReviewCalcitonin gene-related peptideBioinformatics03 medical and health sciencesNitroglycerin0302 clinical medicinemedicineHumans030212 general & internal medicineTryptamines/pharmacologyMigraineTrigeminovascular systembusiness.industryNeuromodulationCluster Headache/bloodCluster headacheAnti-CGRP (receptor) monoclonal antibodies – mAbsMigraine Disorders/bloodTrigeminovascular systemlcsh:RGeneral MedicineCalcitonin gene-related peptide (CGRP)medicine.diseaseDeep Brain Stimulation/statistics & numerical dataNeuromodulation (medicine)Tryptamines3. Good healthCalcitonin Gene-Related Peptide/antagonists & inhibitorsAnesthesiology and Pain MedicineImplantable NeurostimulatorsMigraineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugThe Journal of Headache and Pain
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

The production of the oral mucosa of antiendomysial and anti-tissue-transglutaminase antibodies in patients with celiac disease: a review.

2010

Celiac disease (CD) is a lifelong, T cell—mediated enteropathy, triggered by the ingestion of gluten and related prolamins in genetically susceptible subjects, resulting in minor intestinal mucosal injury, including villous atrophy with crypt hyperplasia and intraepithelial lymphocytosis, and subsequent nutrient malabsorption. Although serological tests for antiendomysial (EMA) and anti—tissue transglutaminase (anti-tTG) autoantibodies are used to screen and follow up on patients with CD, diagnostic confirmation is still based on the histological examination of the small intestinal mucosa. Although the small intestinal mucosa is the main site of the gut involved in CD, other mucosal surface…

medicine.medical_specialtySettore MED/09 - Medicina InternaMalabsorptionGlutensTissue transglutaminaseBiopsyantiendomysial antibodieslcsh:Medicineoral biopsyReview Articlelcsh:TechnologyGastroenterologySensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologySettore MED/28 - Malattie Odontostomatologicheanti–tissue transglutaminase antibodiesInternal medicineBiopsymedicineHumansEnteropathyOral mucosalcsh:ScienceGeneral Environmental ScienceAutoantibodiesSettore MED/12 - GastroenterologiaGastrointestinal tractTransglutaminasesbiologymedicine.diagnostic_testoral mucosalcsh:Tbusiness.industrylcsh:RMouth MucosaMuscle SmoothGeneral Medicinemedicine.diseaseCeliac Diseasemedicine.anatomical_structureceliac disease oral mucosa anti–tissue transglutaminase antibodies antiendomysial antibodies oral biopsy.Immunologybiology.proteinIntraepithelial lymphocytelcsh:QGliadinbusinessTheScientificWorldJournal
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

2019

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…

medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositis
researchProduct

Circulating irisin detection: Does it really work?

2015

The recent discovery of irisin has generated considerable interest in the scientific community. However, many studies on the biochemistry and biology of this intriguing hormone yielded controversial results in humans, which were mostly attributable to a number of drawbacks in the methods used for its detection and measurement.

medicine.medical_specialtyexercisebusiness.industryEndocrinology Diabetes and MetabolismFNDC5Computational biologyFNDC5FibronectinsELISA kit; FNDC5; antibodies; exercise; irisin; mass spectrometryElisa kitEndocrinologyEndocrinologyInternal medicineELISA kitmedicineHumansantibodiesbusinessirisinmass spectrometry
researchProduct

Isolated Anti-HBc: Significance and Management.

2019

Hepatitis B virus (HBV) infection is prevalent worldwide and is associated with dramatic levels of morbidity and mortality. Isolated anti-HBc (IAHBc) is a particular serological pattern that is commonly found in immunocompromised patients. There is ongoing debate regarding the management of patients with IAHBc. Herein, we summarize the current guidelines and the newest evidence. The frequency of IAHBc is variable, with a higher prevalence in some populations, such as persons living with HIV and others immunocompromised patients. The risk of HBV reactivation depends on host factors (including immunosuppression) and viral factors. It is now well established that immunocompromised patients can…

medicine.medical_specialtyisolated anti-HBc antibodiesmedicine.medical_treatmentHbv reactivationHBV reactivationlcsh:Medicineviral hepatitisReviewmedicine.disease_causeSerology03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030203 arthritis & rheumatologyHepatitis B virusimmunosuppressionbusiness.industrylcsh:Rvirus diseasesImmunosuppressionGeneral Medicinemedicine.diseasehepatitis B infectionAnti hbcVaccination030211 gastroenterology & hepatologybusinessViral hepatitismanagementJournal of clinical medicine
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and prot…

2006

ABSTRACTRotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with…

medicine.medical_treatmentMESH : Cytokinesanimal diseasesMESH : Oligodeoxyribonucleotidesmedicine.disease_causeAntibodies ViralImmunoglobulin GMiceIntestinal mucosaMESH: RectumRotavirusMESH : FemaleMESH: AnimalsViralIntestinal MucosaInbred BALB C0303 health sciencesMice Inbred BALB CMESH: CytokinesMESH : Cholera ToxinMESH : Immunoglobulin A SecretoryMESH: Rotavirus Infections3. Good healthMESH : Rotavirus VaccinesVaccinationmedicine.anatomical_structureOligodeoxyribonucleotides[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : RectumMESH: Intestinal MucosaCytokinesMESH: VirionMESH: ImmunizationFemaleAdjuvantMESH : Antibodies ViralCholera ToxinImmunologyMESH: Mice Inbred BALB CSpleenchemical and pharmacologic phenomenaBiologyMicrobiologyMESH : Intestinal Mucosa[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Rotavirus VaccinesRotavirus InfectionsAntibodies03 medical and health sciencesImmune systemVirologyVaccines and Antiviral AgentsMESH : MicemedicineMESH : Rotavirus InfectionsMESH : VirionAnimalsMESH: MiceMESH : Mice Inbred BALB CMESH: Cholera Toxin030304 developmental biology030306 microbiologyRotavirus VaccinesRectumVirionMESH : Immunizationbiochemical phenomena metabolism and nutritionSecretoryVirologyImmunoglobulin AMESH: Immunoglobulin A SecretoryImmunizationInsect ScienceImmunologyImmunoglobulin A Secretorybiology.proteinMESH: OligodeoxyribonucleotidesbacteriaImmunizationMESH : AnimalsMESH: FemaleMESH: Antibodies Viral
researchProduct

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.

2021

Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indications. In order to ensure clinical efficacy and safety aspects, (pre-)clinical experimental approaches evaluate the respective modes of action (MoA). In addition to antigen-specificity including binding affinity and -avidity, MoA comprise Fc-mediated effector functions such as antibody dependent cellular cytotoxicity (ADCC) and the closely related antibody dependent cellular phagocytosis (ADCP). For this reason, a variety of cell-based assays have…

modes of action (MoA)GlycosylationQH301-705.5medicine.drug_classCellReceptors FcReviewBiologyMonoclonal antibodyCatalysisInorganic Chemistrychemistry.chemical_compoundMonoklonaler Antikörper ; effector function ; antibody dependent cellular phagocytosis (ADCP) ; therapeutic monoclonal antibodies (mAbs) ; Fcγ receptor (FcγR) ; modes of action (MoA) ; antibody dependent cellular cytotoxicity (ADCC)medicineAnimalsHumansAvidityClinical efficacyBiology (General)Physical and Theoretical ChemistryReceptorQD1-999Molecular BiologySpectroscopyAntibody-dependent cell-mediated cytotoxicityEffectortherapeutic monoclonal antibodies (mAbs)Organic ChemistryAntibody-Dependent Cell CytotoxicityAntibodies Monoclonalantibody dependent cellular phagocytosis (ADCP)General MedicineFcγ receptor (FcγR)Computer Science ApplicationsImmunoglobulin Fc Fragmentsantibody dependent cellular cytotoxicity (ADCC)Chemistrymedicine.anatomical_structurechemistryImmunologyImmunotherapyeffector functionInternational journal of molecular sciences
researchProduct